Resource Utilization and Cost-Effectiveness of Counselor- vs. Provider-Based Rapid Point-of-Care HIV Screening in the Emergency Department by Walensky, Rochelle P. et al.
Resource Utilization and Cost-Effectiveness of Counselor-
vs. Provider-Based Rapid Point-of-Care HIV Screening in
the Emergency Department
Rochelle P. Walensky
1,2,3,7*, Bethany L. Morris
2, William M. Reichmann
5,9, A. David Paltiel
8, Christian
Arbelaez
6, Laurel Donnell-Fink
5, Jeffrey N. Katz
4,5, Elena Losina
5,7,9
1Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 2Division of General
Medicine, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 3Division of Infectious Disease, Department of
Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 4Division of Rheumatology, Immunology and Allergy, Department of
Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 5Department of Orthopedic Surgery, Brigham and Women’s Hospital, Boston,
Massachusetts, United States of America, 6Department of Emergency Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America,
7Center for AIDS Research, Harvard Medical School, Boston, Massachusetts, United States of America, 8Yale School of Medicine, New Haven, Connecticut, United States
of America, 9Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America
Abstract
Background: Routine HIV screening in emergency department (ED) settings may require dedicated personnel. We evaluated
the outcomes, costs and cost-effectiveness of HIV screening when offered by either a member of the ED staff or by an HIV
counselor.
Methods: We employed a mathematical model to extend data obtained from a randomized clinical trial of provider- vs.
counselor-based HIV screening in the ED. We compared the downstream survival, costs, and cost-effectiveness of three HIV
screening modalities: 1) no screening program; 2) an ED provider-based program; and 3) an HIV counselor-based program.
Trial arm-specific data were used for test offer and acceptance rates (provider offer 36%, acceptance 75%; counselor offer
80%, acceptance 71%). Undiagnosed HIV prevalence (0.4%) and linkage to care rates (80%) were assumed to be equal
between the screening modalities. Personnel costs were derived from trial-based resource utilization data. We examined the
generalizability of results by conducting sensitivity analyses on offer and acceptance rates, undetected HIV prevalence, and
costs.
Results: Estimated HIV screening costs in the provider and counselor arms averaged $8.10 and $31.00 per result received.
The Provider strategy (compared to no screening) had an incremental cost-effectiveness ratio of $58,700/quality-adjusted life
year (QALY) and the Counselor strategy (compared to the Provider strategy) had an incremental cost-effectiveness ratio of
$64,500/QALY. Results were sensitive to the relative offer and acceptance rates by strategy and the capacity of providers to
target-screen, but were robust to changes in undiagnosed HIV prevalence and programmatic costs.
Conclusions: The cost-effectiveness of provider-based HIV screening in an emergency department setting compares
favorably to other US screening programs. Despite its additional cost, counselor-based screening delivers just as much
return on investment as provider based-screening. Investment in dedicated HIV screening personnel is justified in situations
where ED staff resources may be insufficient to provide comprehensive, sustainable screening services.
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Introduction
The revised Centers for Disease Control and Prevention
(CDC) guidelines on HIV screening in 2006 recommend routine
HIV testing in a variety of health care settings [1]. Though
prescriptive with regard to who should be tested, the guidelines
are comparatively vague with regard to who should conduct the
testing. Studies of alternative models whereby HIV counselors
[2], emergency department physicians [2], medical students [3]
or nurses [2,4] have each had the primary responsibility for
conducting HIV testing report variable success in terms of testing
offer and acceptance rates and yield of case identification.
However, no studies to date have reported on the economic
efficiency of these alternative approaches. Our objective was to
evaluate the downstream cost-effectiveness of provider-based vs.
counselor-based HIV screening, using data obtained from a
recently completed clinical trial comparing these two
approaches.
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Analytic Overview
We employed a mathematical simulation model to extend data
obtained from a recently completed randomized clinical trial of
provider- vs. counselor-based HIV screening [5–10]. The model
was used to estimate the survival, downstream resource use, and
incremental cost-effectiveness of the following three rapid, point-
of-care ED HIV screening modalities: 1) no screening program
(for comparison); 2) an ED provider-based HIV screening strategy
(Provider); and 3) a counselor-based HIV screening strategy
(Counselor). Data reported directly from the trial included: rates of
test offer (defined as the percentage of patient encounters during
which the provider explicitly offered a test); rates of test acceptance
(defined as the percentage of instances where patients agreed to be
tested following the offer of a test); and personnel-related direct
costs [10]. Although we rely on testing rates and cost data obtained
from the USHER Trial, we specifically do not use data from the
USHER Trial on case detection as the trial was not powered to
detect a difference in HIV detection rates by trial arm. USHER
testing rates and cost data served as input parameters (Table 1) to
a model-based estimation of per person quality-adjusted life
expectancies and the projected per person lifetime costs. In
accordance with current standards for the conduct of economic
evaluation in health and medicine, all outcomes were measured
from the societal perspective and discounted at 3% per year [11].
Incremental cost-effectiveness was reported in 2009 US dollars per
quality-adjusted life-year gained. We conducted sensitivity analy-
ses, varying base case input parameter values within plausible
ranges to examine their influence on the overall results.
The Cost-Effectiveness of Preventing AIDS Complications
(CEPAC) Model
The CEPAC Model is a mathematical simulation of the
detection, natural history and treatment of HIV disease in the US
[5–9]. The model comprises two main functions: a screening
module that captures HIV detection at the population level; and a
disease module that portrays the progress of HIV infection and
treatment at the patient level. Details of the CEPAC model have
been previously published [5–9].
CEPAC Screening Module. The function of the screening
module is to determine when and if HIV disease is detected and
whether a detected case is successfully linked to care. Detection
can occur via one of three mechanisms: 1) presentation with an
AIDS-defining opportunistic infection; 2) ‘‘background’’ testing, as
currently occurs at sexually transmitted disease clinics, health
insurance visits, in prisons, and with increased frequency in health
care settings; and 3) a dedicated HIV screening program, such as
that examined in the emergency department-based trial. To
present a conservative analysis with regard to the attractiveness of
the dedicated HIV screening program, we assume that
presentation with an AIDS-defining opportunistic infection or
‘‘background’’ testing function with perfect test sensitivity,
specificity and linkage to care. Only upon diagnosis of HIV
disease and successful linkage to care do patients become eligible
for HIV-related care, opportunistic infection prophylaxis, and
antiretroviral therapy according to current guidelines [12,13].
The screening module is equipped to consider alternative
assumptions regarding the occurrence, success, and cost of each
component of the screening encounter. Specifically, the model
tracks rates of test offer, test acceptance among those offered, as
well as test confirmation and linkage to care among patients with
reactive results. We assume that patients encounter background
HIV testing, on average, once every 5 years. That is, everyone in
the population has a monthly chance of background HIV
screening equal to 1/60.
The CEPAC Disease Module. The disease module is a
‘‘state-transition’’ simulation, meaning that the natural history and
clinical management of HIV infection are characterized as a series
of month-to-month transitions between health ‘‘states.’’ These
health states are defined by CD4 count (.500/mL; 351–500/mL;
201–350/mL; 101–200/mL; 51–100/mL; ,50/mL), HIV RNA
(viral load) level (.100,000 copies/ml, 30,001–100,000 copies/ml;
10,001–30,000 copies/ml; 3,001–10,000 copies/ml; 501–3,000
copies/ml; 0–500 copies/ml) as well as treatment and
opportunistic infection history. Health states are assumed to be
predictive of: further disease progression; both therapeutic and
adverse responses to therapy; the development of additional co-
morbidities and mortality; and the resource use associated with
each of these outcomes. The model is implemented as a ‘‘Monte
Carlo simulation,’’ meaning that a random number generator and
a set of estimated probabilities are used to determine the state-to-
state pathway followed by an individual, hypothetical patient.
In the CEPAC disease model, higher HIV RNA levels are
associated with faster rates of CD4 decline [14] while lower CD4
cell counts are associated with an increased frequency of AIDS-
related opportunistic infections [15]. Primary prophylaxis against
common opportunistic infections (e.g. Pneumocystis jiroveci, toxo-
plasmosis, Mycobacterium avium complex) is provided according
to current guidelines [13]. Deaths in the model are attributable to
HIV-related causes, opportunistic infections, or to age-, sex- and
race-adjusted background mortality rates [16–18].
In accordance with US-based guidelines, HIV-infected patients
with detected infection in the model undergo quarterly clinical
evaluation with CD4 and HIV RNA laboratories [12]. Antiret-
roviral therapy is initiated when CD4 counts fall below ,500/ml
[12]. The model specifies six sequential antiretroviral regimens
with progressively decreasing efficacy, defined as percent achieving
HIV RNA suppression and immunologic benefit (CD4 increase,
Table 2) [19–25]. Treatment failure and decisions regarding
regimen switches are based upon virologic rebound that is
detected with an HIV RNA test.
Input Parameters
Input parameters pertaining to the clinical and economic
outcomes of the HIV testing process for both the counselor- and
provider-based screening strategies were obtained from the
Universal Screening for HIV in the Emergency Room (USHER)
Trial [10,26–29]. Other HIV natural history and treatment-
related data were derived from public use data sets and published
estimates [14–17,19–25,30,31].
The USHER Trial: data collection and analysis
The USHER Trial was a randomized trial to examine
differences in counselor- vs. provider-based HIV screening in the
emergency department (ED) [10]. Details of the trial protocol and
clinical outcomes have been reported elsewhere [10,26–29]. In
brief, after being registered, triaged, and escorted to the patient
care area to be evaluated for their chief medical complaint, eligible
and consenting ED patients were randomized to be offered HIV
screening and complete the HIV testing process either by a
dedicated HIV counselor employed by the trial or by a member of
the current ED staff. Eligibility criteria, Massachusetts-specific
Counselor vs. Provider HIV Screening
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Variable Base Case Value Range Examined Reference
Baseline cohort characteristics
Undiagnosed HIV prevalence (%) [10]
Total 0.4 0.1–1.0
Age, mean years (SD) 37 (14) 27–47 [10]
Sex [10]
Male (%) 35
Distribution of initial CD4, median cells/ml (IQR, SD)
Chronic HIV infection* 467 (606, 471) [10]
Discount Rate (annual) 3% 0–3%
HIV RNA distribution in chronic HIV infection (%) [15,31]
.100,000 copies/ml 12.9
30,001–100,000 copies/ml 12.9
10,001–30,000 copies/ml 25.0
3,001–10,000 copies/ml 25.2
501–3,000 copies/ml 16.3
,500 copies/ml 7.7
HIV testing protocols
Average background HIV test frequency Every 5 yrs Every 3–7 yrs [8]
Sensitivity{ (%) 99.6 [8,32–35]
Specificity{ (%) 97.5 [8,32–35]
Provider strategy
Test offer probability (%) 36 30–100 [10]
Test acceptance probability (%){ 75 30–100 [10]
Probability of HIV-detected to link to care (%) 80 50–100 [10]
Counselor strategy
Test offer probability (%) 80 30–100 [10]
Test acceptance probability (%){ 71 30–100 [10]
Probability of HIV-detected to link to care (%) 80 50–100 [10]
Costs (2009 US$)
Routine care (range by CD4, monthly) , off ART 290–2,380 [37–39]
Routine care (range by CD4, monthly), on ART 240–1,080 [37–39]
CD4 test 70 [40]
HIV RNA test 120 [40]
Acute OI events [37–39]
Pneumocystis jiroveci pneumonia 13,120
Mycobacterium avian complex 5,620
Toxoplasmosis 31,320
Cytomegalovirus 8,010
Fungal infections 8,930
Other opportunistic infections 6,010
Mortality (treated and untreated patients) [37–39]
Any OI event 93,990
Chronic AIDS 59,670
SD: Standard deviation; IQR: Inter-quartile range; OI: Opportunistic infection.
*Starting CD4 cell count, on average, for prevalent cases.
{Sensitivity and specificity refer to the characteristics of a single rapid test, not the confirmatory process; test sensitivity is assumed to be 2.5% (the false positive rate)
during the acute infection window period (approximately 2 months).
{Probability of test acceptance is conditional upon being offered a test.
doi:10.1371/journal.pone.0025575.t001
Counselor vs. Provider HIV Screening
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have been previously described [10]. Data from this trial included
population age and gender distributions, undiagnosed HIV
prevalence, and clinical parameters (CD4, HIV RNA) among
newly detected cases (Table 1).
‘‘Coverage’’ for each program. We defined the ‘‘coverage’’
of a screening program as the product of two probabilities: the
likelihood that a test was offered; and the likelihood that an offered
test was accepted. In the provider arm of the USHER Trial, 36% of
participants were offered a test and 75% of these participants
accepted. In the counselor arm of the USHER Trial, 80% of
subjects were offered a test and 71% of these accepted. Thus,
baseline coverage in provider- and counselor-based programs was
(0.36*0.75) 27% and (0.80*0.71) 57%, respectively. We conducted
sensitivity analyses using coverage levels from 9% to 100% for both
programs, as implied by the parameter ranges listed in Table 1.
Testing program success hinges on linking participants with
reactive results to care. Since the USHER Trial data did not
suggest significant differences between study arms, we applied the
80% overall linkage to care rate observed in the trial to both
programs.
Prevalence of undetected HIV. Among subjects tested in
the provider arm, the HIV prevalence was 7/631 (1.1%); among
those tested in the counselor arm the HIV prevalence was 0/1,371
(0%) [10]. Although new HIV diagnoses differed in the two arms
of the USHER Trial, we did not employ these values to estimate
arm-specific levels of undetected HIV prevalence for our base case
analysis. Our reason for choosing to ignore this disparity was that
our goal was not to examine alternative testing strategies on
different targeted populations with varying underlying HIV
prevalences. Instead, we examined different strategies applied to
a single population with a single undiagnosed prevalence. Our
base case scenario therefore assumed a more plausible underlying
prevalence of 0.4%, which we applied to both test accepters and
refusers in both trial arms. It is a key assumption of our analysis
that both Provider and Counselor strategies involved the offer of a test
to a random sampling of this underlying population.
The observed difference in the yield of new HIV cases in the
two trial arms was notable enough to prompt us to conduct
extensive sensitivity analysis on the prevalence assumption: first, by
altering HIV prevalence in both arms simultaneously; and second,
by keeping the overall HIV prevalence constant but increasing the
HIV prevalence among those offered/accepting in the provider
arm to 1.0%, thereby simulating provider potential capacity to
target testing to persons at elevated risk of infection, as was
suggested by the USHER Trial.
Test performance. We applied the performance characteristics
of the screening test used in the USHER Trial: the
OraQuickHADVANCE
TM Rapid HIV 1/2 Antibody Test, with a
reported sensitivity of 99.6% and a specificity of 97.5% [8,32–35].
Participants with reactive rapid test results were asked to consent to a
confirmatory HIV test (EIA and Western Blot), as well as to CD4 and
viral load testing to evaluate eligibility for immediate antiretroviral
therapy.
Resource utilization: the USHER provider arm. In the
provider arm, nursing assistants offered the HIV screening test,
obtained written informed consent and conducted the oral point-
of-care rapid test. Non-reactive results were communicated to the
patient by the house officer (resident); reactive results were
communicated by the attending physician in the Emergency
Department [10]. We calculated resource use in the provider arm
based on the following data collected from providers in the trial:
minutes spent offering the HIV test; minutes spent conducting the
test; whether a test result was provided to the patient (and, if so,
what the result was); and minutes spent on review of the result.
Table 3 provides the total number of patient-contacts for each of
these events over a one-year trial period and the annual salary for
each of these provider types. Annual salaries and average hourly
work weeks were obtained from the Brigham and Women’s
Emergency Department and are consistent with national or
regional averages [36]. Because different staff members in the
Emergency Department conducted different aspects of these
activities, these resource utilization data (mean time per patient)
were converted into dollars (2009 US$) for each activity (mean cost
per patient). We then multiplied the total number of annual trial
participants (N, second column, Table 3) by the mean cost per
patient for each activity (sixth column); adding each of the
activities resulted in a sum of $3,565. To estimate the cost per
result received, we divided $3,565 by 440 (the total number
receiving results). We excluded downtime in the cost calculations
Table 2. Antiretroviral therapy input parameters for model-based analyses.
Variable Base Case Value Monthly Cost (US$) Reference
Antiretroviral therapy efficacy: % HIV RNA suppression at 24 weeks, mean increase in CD4 cell count at 48 weeks
First line 86.0 1,430 [19,25,30]
190 cells/ml
Second line 73.3 2,050 [21,22,30]
110 cells/ml
Third line 61.3 2,040 [21,22,30]
121 cells/ml
Fourth line 64.5 2,630 [20,30]
102 cells/ml*
Fifth line 40.0 4,000 [23,24,30]
121 cells/ml
Sixth line 15.0 1,740 [24,30]
45 cells/ml
*At 24 weeks.
doi:10.1371/journal.pone.0025575.t002
Counselor vs. Provider HIV Screening
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e25575of the provider arm, as we assumed any downtime would be filled
with other clinical duties
Resource utilization: the USHER counselor arm. In the
counselor arm of the USHER Trial, all HIV screening activities were
conducted by the counselor, including test offer, test development,
and reporting of non-reactive and reactive test results to participants.
The results were given prior to or during the patient encounter with
the ED provider to address their chief clinical complaint.
Table 4 also provides the total patient encounters for each
activity, as well as the mean time per patient for each encounter as
collected by the data instrument in the trial. While these provide
interesting comparisons to the provider data, they were not
specifically used for calculating per-result received counselor costs.
Instead, we were careful in the counselor arm analyses to include
counselor downtime, thereby capturing all expenses incurred by
hiring new personnel. Downtime also accounted for limitations
resulting from insufficient ED patients to keep counselors busy to
capacity at all times. For cost-related input parameters for the cost-
effectiveness analysis, we therefore divided the annual counselor
salary by the number of patients per year per counselor receiving
test results in the counselor arm ($32,000/1,032).
Other costs. In addition to the immediate costs of the testing
program, the CEPAC model considers the HIV-associated direct
medical resource use – above and beyond background medical care
– resulting from the downstream outcomes of the testing program
[37–41]. These costs include inpatient days, outpatient visits,
laboratory tests, and medication costs. Indirect costs (e.g. patient
time and lost wages) and direct non-medical costs are excluded.
Results
Resource utilization and costs derived from the USHER
Trial
Provider Program. In the provider arm, an average of
4.44 minutes of a nursing assistant’s time were spent offering HIV
testing to each trial participant, translating to a cost of $1.18 per
patient offered (Table 3). On average, nursing assistants spent
20 minutes conducting and developing the test for those who
accepted, adding $5.33 per patient tested. Review of non-reactive
results by house officers required an average of 1.61 minutes
($0.47/negative result), and review of reactive results by attending
physicians averaged 14.85 minutes ($19.99/reactive result). Thus,
the average cost per test received for the provider strategy,
calculated as a weighted average of positive and negative results,
was $8.10.
Table 3. Resource utilization and costs from the USHER Trial Provider Arm.
N (per year)
Responsible staff
member
Mean annual
salary (mean
weekly hours)
Mean time per
patient (minutes,
SD)
Mean cost
per patient
cost (US$)
Total cost for activity
for all patients (N*per
patient cost) (US$)
PROVIDER ARM
HIV test offer 608 Nurse Assistant $33,280* (40) 4.44 (3.92) 1.18 720
Conducting HIV Test 440 Nurse Assistant $33,280* (40) 20 5.33 2,347
Reviewing results (neg) 425 House Officer $54,336{ (60) 1.61 (1.63) 0.47 199
Review results (reactive) 15 Attending Physician $210,000{ (50) 14.85 (19.39) 19.99 300
Total costs for all activities 3,565
Cost per result received 8.10
SD: Standard deviation.
*Obtained from Brigham and Women’s Hospital, Emergency Department budgets.
{Based on average salaries post-graduate year 1–4 emergency medicine resident salaries for the 2008–2009 academic year; assumes a 60-hour resident work week.
{Based on median BWH attending physician salary in calendar year 2008; assumes a 50-hour attending work week. Results are consistent with AAMC northeast region,
emergency medicine 2008 average, when weighted by academic rank [36].
doi:10.1371/journal.pone.0025575.t003
Table 4. Resource utilization and costs from the USHER Trial Counselor Arm.
N (per counselor
per year)
Responsible
staff member
Mean annual
salary (mean
weekly hours)
Mean time per
patient (minutes,
SD)
Mean cost per
patient (US$){
COUNSELOR ARM
HIV test offer 1,498 Counselor $32,000 (40) 3.82 (3.21) 0.98
Conducting HIV Test 1,032 Counselor $32,000 (40) 20 5.13
Reviewing results (neg) 1,008 Counselor $32,000 (40) 1.51 (1.22) 0.39
Review results (reactive) 24 Counselor $32,000 (40) 9.83 (8.17) 2.52
Cost per result received* 31.00
SD: Standard deviation.
*The estimate was obtained by dividing the annual counselor salary by the number of patients per year per counselor receiving test results in the counselor arm. We
have intentionally applied a conservative calculation of the cost per result received in the counselor arm, by accounting for all counselor downtime.
{Costs in this column are exclusive of downtime; this column multiplies the mean time per patient by the cost per minute of a counselor. This column is shown simply
for comparison to the provider strategy and is not used in the cost-effectiveness analysis.
doi:10.1371/journal.pone.0025575.t004
Counselor vs. Provider HIV Screening
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counselor (annual salary=$32,000) tested and delivered valid
results to an average of 1,032 participants; the cost per subject who
received his/her test results was: ($32,000/1,032)=$31.00
(Table 4).
Cost-effectiveness Analysis: Base Case
Discounted (undiscounted) quality-adjusted life expectancies for
HIV-infected persons were 119.61, 125.88, and 132.72 (170.56,
181.37, and 193.21) months in the No Screen, Provider and Counselor
strategies, respectively (Table 5). Improved survival in the two
screening strategies also increased the projected discounted per
person lifetime costs: No Screen=$1,040; Provider strategy=$1,160;
and Counselor strategy=$1,310. The incremental cost-effectiveness
ratio of the Provider strategy, compared to No Screen was $58,700/
quality-adjusted life year (QALY). The incremental cost-effective-
ness ratio of the Counselor strategy, compared to the Provider
strategy, was $64,500/QALY.
Sensitivity Analyses
Undetected HIV Prevalence and Program Costs. Using
program participation rates from the USHER Trial, the
incremental cost-effectiveness ratio of the Provider strategy,
compared to No Screen, ranged from $68,700-$56,700/QALY at
HIV prevalences ranging from 0.1–1.0% (open circles, solid gray
line in Figure 1). The Counselor strategy, compared to the Provider
strategy, maintained an incremental cost-effectiveness ratio below
$100,000/QALY at undetected HIV prevalences higher than
0.1% (solid squares, solid black line). Measured by widely accepted
standards of value in health [42], this suggests a relative
insensitivity to both programmatic costs and prevalence,
assuming that the prevalence is balanced between arms. As
undetected HIV prevalences approached 1.0%, the incremental
cost-effectiveness ratio of the Counselor strategy approached that of
the Provider strategy ($59,300/QALY vs. $56,700/QALY).
In a two-way sensitivity analysis on personnel costs and
undetected HIV prevalence for each strategy (Figure 1, dotted
lines), results were insensitive to a doubling of counselor costs
($62.00/result received, dotted line solid squares) or a halving of
provider costs ($4.05/result received, dotted line, open circles).
In further sensitivity analyses, we examined the case where
providers could identify persons at higher risk of HIV infection
and therefore ‘‘target screen.’’ If the underlying prevalence among
patients targeted by providers was 1% – and therefore that in the
population tested by counselors was a much lower 0.18% – then
the Counselor strategy was weakly dominated by the Provider strategy
and the cost-effectiveness of the Provider strategy was slightly more
attractive ($55,600/QALY, Table 5, bottom).
Screening Coverage by Program. Figure 2 (solid squares)
illustrates how the incremental cost-effectiveness ratio of the
Counselor strategy varied when coverage in the Provider strategy was
held constant at 27% and coverage in the Counselor strategy ranged
from 28–100%. The incremental cost-effectiveness of the Counselor
strategy sharply increased when counselor-based program
coverage approached that of the Provider strategy and was less
than 30%. When coverage in the Counselor strategy was instead
held constant at 57% and coverage in the Provider strategy was
varied between 2.0–54%, the incremental cost-effectiveness of the
Counselor strategy sharply increased as coverage in the Provider
strategy approached that in the Counselor strategy (i.e., .52%).
When program coverage in the Provider strategy exceeded that in
the Counselor strategy, the Provider strategy was preferred given that
the Provider strategy was both less expensive and more effective.
Other Sensitivity Analyses. When the CD4 cell count of the
newly identified HIV-infected cohort was lower (mean 100/ml), the
incremental cost-effectiveness ratios in all strategies were more
attractive (Provider, compared to No Screen $41,200/QALY;
Counselor, compared to Provider $43,900/QALY). In other
sensitivity analyses, the incremental cost-effectiveness results of
the Counselor strategy were robust to the frequency of background
testing (range from, on average, every 3–7 years), the average age
of cohort initiation, ART efficacy, and the discount rate.
Discussion
We used data from the USHER Trial to inform a critical,
policy-relevant question regarding the revised HIV screening
guidelines: does the economic efficiency of HIV screening depend
on how the screening programs are designed and staffed? We
found that counselor-based, compared to provider-based, routine
HIV screening in an emergency department setting is cost-
effective, as assessed by contemporary criteria for cost-effectiveness
[11,42]. With very similar cost-effectiveness ratios for the two
rapid, point-of-care screening programs, the results also suggest
roughly the same return on investment from counselor-based and
provider-based screening. Why? Because, the mechanics of the
Table 5. Base case cost-effectiveness analyses of Counselor vs. Provider strategies.
Undiscounted HIV-
infected QALE
(months)
Undiscounted
Population QALE
(months)
Discounted HIV-
infected QALE
(months)
Discounted
Population QALE
(months)
DiscountedPer
person Population
lifetime costs ($)
Incremental cost-
effectiveness ratio
($/QALY)*
Base case
No screening program 170.56 364.15 119.61 218.38 1,040 –
Provider Strategy 181.37 364.19 125.88 218.40 1,160 58,700
Counselor Strategy 193.21 364.24 132.72 218.43 1,310 64,500
‘‘Target testing’’ in provider arm: 1% prevalence among those tested in that arm (0.18% among those not tested)
No screening program 170.56 364.15 119.61 218.38 1,040 –
Counselor Strategy 193.21 364.24 132.72 218.43 1,310 dominated{
Provider Strategy 197.37 364.26 135.19 218.44 1,330 55,600
QALE: Quality-adjusted life expectancy, QALY: quality-adjusted life year.
*Cost-effectiveness ratios using discounted per person lifetime costs and discounted per person QALE were calculated prior to rounding.
{‘‘dominated’’ strategies are eliminated because they cost more and deliver fewer years of life saved than the comparative combination of strategies [11].
doi:10.1371/journal.pone.0025575.t005
Counselor vs. Provider HIV Screening
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long-term benefits. What drives both costs and benefits in the long-
run is the pathway of care and treatment triggered whenever and
however a case of infection is detected and successfully linked to
care. Consequently, whichever program maximizes the total
number of patients linked to care is the better choice. Findings
in favor of counselor-based screening were robust under
assumptions intended to generalize our results beyond the
USHER Trial setting including variations in undiagnosed HIV
prevalence and programmatic costs.
Our results are consistent with previous studies linking the cost-
effectiveness of HIV testing to the costs and benefits of
downstream HIV care [7,43]. Those studies are founded upon
the grounds that HIV-infected individuals have an enormous
amount of health benefit to gain from routine access to HIV care
[9] – benefits that could not be realized without an HIV diagnosis.
Cost-effectiveness studies also demonstrate the relative insensitivity
of those findings to HIV screening costs [44]; the fact that
screening costs can increase 10-fold without impacting cost-
effectiveness results is due to the comparatively small component
of screening costs in the overall costs of care that HIV-infected
patients ultimately generate. More recent work has reported that,
on a national level, the revised HIV screening guidelines will cost
$2.7 billion over the next 5 years; only 18% of that budget increase
is due to testing costs [45].
Although testing costs have little influence on the cost-
effectiveness ratios, such costs are critical to the budgetary
planning of screening program development. Indeed, a cost-
effective program must also be affordable for it to be effectively
implemented, and the affordability of new counseling personnel
must be seriously considered. Our findings regarding the resource
utilization required of emergency medicine personnel to conduct
HIV testing were consistent with a survey of HIV screening costs
in 45 hospitals [46]. We note that the approximate 5 minutes
required for ‘‘test offer’’ is likely an overestimate for most other
settings now that laws requiring time-intensive, written informed
consent for HIV screening have been amended in most states.
Among the biggest time and cost commitments in the provider
arm of the USHER Trial was the delivery of reactive results by the
attending physician. Though these events are relatively rare in any
domestic screening program, it should be recognized that newly
diagnosed HIV-infected patients will require due time and
attention. This time may be hard for a busy emergency
department staff to allocate but is essential to a clinically sensitive
screening environment.
These results hinge upon the practical truth that in most ED
settings, current staff are stretched too thin to perform point-of-
care rapid HIV tests on all ED patients and to provide the
spectrum of support services that such testing would require.
Hiring of relatively inexpensive personnel, like HIV counselors, to
improve screening coverage is worth the investment. However, if
the current ED personnel have the capacity to increase coverage –
such that screening program participation approaches that of the
counselors – the value of additional personnel is diminished.
Results are also sensitive to the capacity of ED providers to
‘‘target’’ screen their patients; that is, the providers’ ability to
identify and test those patients at highest risk for HIV infection.
While providers may excel at recognizing and testing patients who
present with symptoms consistent with an AIDS-defining illness,
such clinical presentations are relatively rare. Previous reports
have demonstrated that providers often do not routinely nor
comfortably inquire about sexual and substance use habits [47–
50]. Some findings from the USHER Trial suggest that providers
preferentially tested younger patients: the rate of test offer was
similar across all ages in the counselor arm, but decreased with
increasing age in the provider arm. However, among the factors
Figure 1. Sensitivity of incremental cost-effectiveness ratio (vertical axis) to alternative undetected HIV prevalences (horizontal
axis). The incremental cost-effectiveness of the Provider strategy, compared to No Screen, is shown by the open circles. The incremental cost-
effectiveness of the Counselor strategy, compared to the Provider strategy is provided by the closed squares. The dashed line (open circles) is the
incremental cost-effectiveness of the Provider strategy, compared to No Screen, at half the base case provider-based screening costs ($4.05/result
received). The dashed line (solid squares) is the incremental cost-effectiveness of Counselor strategy, compared to the Provider strategy, at twice the
base case counselor-based screening costs ($62.00/result received).
doi:10.1371/journal.pone.0025575.g001
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offer rates, stratified by subjects’ self-reported high sexual or
substance abuse risk; differences in provider offer rates may well
exist among unmeasured factors [10].
Placing program efficacy and efficiency outcomes side-by-side
highlights important trade-offs demonstrated in the USHER Trial.
Provider-based screening is cheaper on a per result basis.
However, weaving HIV screening activities into the demands on
the time of an already overstretched staff has its downsides – fewer
patients may be tested. In contrast, hiring dedicated counselors for
these activities ensures that a greater number of patients actually
receive an HIV test but does so at greater costs. Our cost-
effectiveness results suggest that there is good value to be obtained
by investing in larger, counselor-based HIV case identification.
Notably, the efficacy-versus-efficiency tradeoff may become less
stark in the future. With streamlined consent processes and
advancing technology for non-rapid HIV tests, it may soon be
feasible to HIV screen all phlebotomized emergency department
patients [51,52] without ancillary staff [53]. That such programs
are still hindered by lower rates of linkage to care speaks to the
continued need for counselor support and the applicability of our
results.
Our results have several noteworthy limitations. First, Massa-
chusetts remains one of three states where laws requiring written
informed consent for HIV testing persist. Per person testing costs
in both trial arms may be higher than those observed in states with
more streamlined testing. However, all of our results point to the
robustness of our findings in the face of varying program costs.
Second, we employed data obtained directly from the USHER
Trial to develop base case estimates of test offer, acceptance and
resource utilization parameters for both the Provider and Counselor
strategies. Importantly, a single base case value of 0.4% was
estimated for the prevalence of undetected HIV, and this value
was applied to both the Provider and Counselor strategies in our
analysis. In the base case, we chose not to make use of the
difference in new HIV diagnoses observed in the two arms of the
USHER Trial (7/631 in the provider arm versus 0/1371 in the
counselor arm). We made this choice because we intended to
examine the cost-effectiveness of alternative HIV screening
strategies when applied to a single population of ED clients, not
to two differing populations of such clients. Since the USHER
Trial findings suggested some degree of targeting in the provider
arm, we did conduct extensive sensitivity analyses assuming
different prevalence values for patients served by providers and
Figure 2. Sensitivity of incremental cost-effectiveness ratio (vertical axis) to HIV testing program coverage (horizontal axis). The
squares provide the cost-effectiveness of the Counselor strategy compared to the Provider strategy at alternative rates of counselor-based program
coverage; provider participation is held constant at its base case value (27%). Counselor-based testing is cost-effective at a ratio of ,$100,000/QALY
so long as counselor-based program coverage exceeds 30%. The circles illustrate the incremental cost-effectiveness of Counselor strategy to Provider
strategy testing at alternative rates of provider-based program coverage; counselor-based coverage is held constant at its base case value (57%).
doi:10.1371/journal.pone.0025575.g002
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describing areas where programs may function differently,
including rates of test offer and acceptance. Because the cost-
effectiveness results were sensitive to the difference in prevalence
by testing strategy, we urge readers to interpret our conclusions
regarding the comparative value of the Counselor strategy – and the
important impact of the potential for providers to target test – with
caution.
Finally, our analysis does not capture the large potential impact
of improved case detection on secondary HIV transmission. Our
failure to estimate ART’s preventive benefits to the broader
population remains a handicap that almost certainly understates
both the health benefits and cost-effectiveness findings reported
here. We believe that our modeling approach can be justified on
the grounds that it is conservative – i.e., taking the preventive
benefits of ART into consideration would only serve to strengthen
the already-favorable findings. However, we also acknowledge that
there is an important qualitative difference between an attractive
incremental cost-effectiveness ratio of ,$60k/QALY and an even-
more-attractive ratio several tens of thousands of dollars smaller
and that this difference may, in fact, result in policy differences in
some settings. Therefore, incorporating population-level transmis-
sion benefits into future analyses represents an important next
step.
We found that HIV screening in the emergency department
setting – whether conducted by emergency department staff or
dedicated counselors – resulted in screening costs ranging from
$8–$31 per test result received. While provider-based screening
was cheaper on a per result-received basis, counselor-based testing
ultimately screened more patients and conferred sufficient value
($64,500/QALY) to justify the additional outlay. However, cost-
effectiveness does not imply affordability. In settings where
resources may be insufficient to support the implementation of
full-scale, counselor-based screening, provider-based approaches
will continue to represent an excellent, cost-effective alternative to
no screening at all.
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